Los Avances en Cancerologia año 2007, según ASCO


Published on

Published in: Health & Medicine, Business
1 Like
  • Be the first to comment

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Los Avances en Cancerologia año 2007, según ASCO

  1. 1. Clinical Cancer Advances 2007Clinical Cancer Advances 2007
  2. 2. Clinical Cancer Advances 2007 Third annual Clinical Cancer Advances report from ASCO, identifying most significant clinical cancer research of past year Six most important advances identified, along with 18 other notable advances in prevention, screening, treatment, and survivorship Overseen by 21-member oncologist editorial board Available as PDF at www.plwc.org; also published in the Journal of Clinical Oncology, www.jco.org
  3. 3. Top Six Advances 1. First Systemic Treatment for Primary Liver Cancer: A large study found that patients who took the targeted therapy sorafenib (Nexavar) for advanced liver cancer lived about 44 percent longer than patients who did not. Primary liver cancer is the third leading cause of cancer death globally.
  4. 4. Top Six Advances 2. Treatments for Advanced Kidney Cancer Continue to Expand: Adding bevacizumab (Avastin) to standard kidney cancer treatment nearly doubled progression-free survival. Several targeted therapies have proven effective in recent years, giving patients a range of new treatment options.
  5. 5. Top Six Advances 3. MRI Better for Screening Women at High Risk of Breast Cancer: Use of magnetic resonance imaging (MRI) versus mammography has generated significant debate. This year, new guidelines based on findings from several studies show for the first time that MRI can be effectively used in women at high risk (1.4 million U.S. women) of developing cancer. MRI is still not yet recommended for most women as a breast cancer screening tool.
  6. 6. Top Six Advances 4. HPV Linked to Head and Neck Cancers; Possible New Role for HPV Vaccine: Two studies show that the human papillomavirus (HPV) was found in 72 percent of several types of head and neck cancers, and the virus’s presence was linked to better treatment outcomes. These findings suggest a possible role for the new HPV vaccine in preventing head and neck cancers, though additional study is needed.
  7. 7. Top Six Advances 5. Drop in Breast Cancer Cases Linked to Declining Use of Hormone Replacement Therapy: Two studies this year reported that the recent significant reduction in breast cancer incidence appears to be linked to the declining use of hormone replacement therapy (HRT) in menopausal women since 2002.
  8. 8. Top Six Advances 6. Preventive Radiation Therapy Can Stop Spread of Advanced Lung Cancer: Researchers reported for the first time that “whole brain” radiation therapy for patients with advanced small cell lung cancer cuts the risk that the cancer will spread to the brain by about two- thirds, and as a result doubled one-year survival rates. These patients’ outlook has historically been very poor.
  9. 9. In the report, ASCO makes two major recommendations: 1. Renew Nation’s Investment in Cancer Research The budgets for the NIH and the NCI have remained unchanged for four years, marking the longest sustained period of flat government funding for cancer research in the country’s history. To reverse the effects of these cuts and maintain the nation’s world-class research infrastructure, ASCO calls for substantial funding increases for NIH and NCI, at a minimum to keep pace with medical inflation.
  10. 10. 2. Remove Barriers to Clinical Trial Participation Cancer trials are the engine of cancer research and can represent a patient’s best chance for effective therapy, but data suggest that only about 5 percent of cancer patients currently participate. ASCO’s report calls for public and private insurers to cover the costs of patients’ participation. Some insurers do not cover participation in clinical trials because they are classified as “experimental.” Several states have passed legislation or established agreements requiring that health plans pay for routine medical care for patients in clinical trials. ASCO urges other states to do the same, and encourages Medicare to continue to cover trial participation.
  11. 11. More About the Report Clinical Cancer Advances was developed under the guidance of a 21- person editorial board made up of leading oncologists and other cancer specialists, including specialty editors for each of the disease- and issue-specific sections. Editors of the report reviewed studies published in peer-reviewed scientific journals and early results of research presented at major scientific meetings over a one-year period (November 2006-October 2007). Only studies that significantly altered the way a cancer is understood or had an important impact on patient care were included.
  12. 12. For additional information, contact Todd Bentsen, Senior Manager, Media Relations, bentsent@asco.org, 703-519-2925